# A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

> **NCT05933187** · PHASE1 · COMPLETED · sponsor: **Cerevel Therapeutics, LLC** · enrollment: 15 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Treatment A: Emraclidine 30mg IR tablets (reference)
- **DRUG:** Treatment B: Emraclidine 30mg IR test tablets 1
- **DRUG:** Treatment C: Emraclidine 30mg IR test tablets 2
- **DRUG:** Treatment D: Emraclidine 30mg IR test tablets 3

## Key facts

- **NCT ID:** NCT05933187
- **Lead sponsor:** Cerevel Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-19
- **Primary completion:** 2023-09-12
- **Final completion:** 2023-09-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933187, "A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05933187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*